This study is for people with advanced HER2+ breast cancer whose cancer has spread to the brain but is stable elsewhere. It tests if adding the drug tucatinib to their current standard treatment can help keep the brain tumors from growing back longer. About 48 participants will r…
Phase: PHASE2 • Sponsor: Carey Anders, M.D. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC